JP2016510343A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510343A5 JP2016510343A5 JP2015558130A JP2015558130A JP2016510343A5 JP 2016510343 A5 JP2016510343 A5 JP 2016510343A5 JP 2015558130 A JP2015558130 A JP 2015558130A JP 2015558130 A JP2015558130 A JP 2015558130A JP 2016510343 A5 JP2016510343 A5 JP 2016510343A5
- Authority
- JP
- Japan
- Prior art keywords
- laquinimod
- multiple sclerosis
- subject
- progressive multiple
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 27
- 229960004577 laquinimod Drugs 0.000 claims 27
- 206010053395 Progressive multiple sclerosis Diseases 0.000 claims 10
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 8
- 208000024891 symptom Diseases 0.000 claims 6
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 4
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 4
- 208000024806 Brain atrophy Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000000750 progressive effect Effects 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 210000002804 pyramidal tract Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361765394P | 2013-02-15 | 2013-02-15 | |
| US61/765,394 | 2013-02-15 | ||
| US201361911106P | 2013-12-03 | 2013-12-03 | |
| US61/911,106 | 2013-12-03 | ||
| PCT/US2014/016278 WO2014127139A1 (en) | 2013-02-15 | 2014-02-13 | Treatment of multiple sclerosis with laquinimod |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016510343A JP2016510343A (ja) | 2016-04-07 |
| JP2016510343A5 true JP2016510343A5 (enExample) | 2017-03-16 |
Family
ID=51351655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558130A Pending JP2016510343A (ja) | 2013-02-15 | 2014-02-13 | ラキニモドを用いる多発性硬化症の治療 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140235670A1 (enExample) |
| EP (1) | EP2956137A4 (enExample) |
| JP (1) | JP2016510343A (enExample) |
| KR (1) | KR20150119227A (enExample) |
| CN (1) | CN105163737A (enExample) |
| AU (1) | AU2014216199A1 (enExample) |
| BR (1) | BR112015019564A2 (enExample) |
| CA (1) | CA2900503A1 (enExample) |
| CL (1) | CL2015002181A1 (enExample) |
| EA (1) | EA201591507A1 (enExample) |
| HK (2) | HK1218254A1 (enExample) |
| IL (1) | IL240014A0 (enExample) |
| MX (1) | MX2015010296A (enExample) |
| PE (1) | PE20151526A1 (enExample) |
| SG (1) | SG11201505818WA (enExample) |
| TW (1) | TW201442709A (enExample) |
| UY (1) | UY35328A (enExample) |
| WO (1) | WO2014127139A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR089862A1 (es) | 2012-02-03 | 2014-09-24 | Teva Pharma | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| KR20170005434A (ko) | 2014-04-29 | 2017-01-13 | 테바 파마슈티컬 인더스트리즈 리미티드 | 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드 |
| WO2016059571A1 (en) * | 2014-10-16 | 2016-04-21 | Novartis Ag | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis |
| US10091217B2 (en) | 2016-06-21 | 2018-10-02 | Logrhythm, Inc. | Risk based priority processing of data |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| BR112019017724A2 (pt) * | 2017-03-26 | 2020-03-31 | Mapi Pharma Ltd. | Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla |
| EP4178675A4 (en) * | 2020-07-09 | 2024-08-07 | Oklahoma Medical Research Foundation | BIOMARKERS FOR THE IDENTIFICATION OF RELAPSES IN MULTIPLE SCLEROSIS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| KR20150065951A (ko) * | 2006-06-12 | 2015-06-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| PT2187882E (pt) * | 2007-07-11 | 2013-04-17 | Medicinova Inc | Tratamento de uma doença neurodegenerativa progressiva com ibudilast |
| TW201438738A (zh) * | 2008-09-16 | 2014-10-16 | 建南德克公司 | 治療進展型多發性硬化症之方法 |
| AU2009324495B2 (en) * | 2008-12-11 | 2015-12-24 | Biovista, Inc. | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles |
| EP2442651B1 (en) * | 2009-06-19 | 2015-07-29 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| CA2820586A1 (en) * | 2010-12-07 | 2012-06-14 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| SG10201606204TA (en) * | 2011-07-28 | 2016-09-29 | Teva Pharma | Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| US20140107154A1 (en) * | 2012-10-12 | 2014-04-17 | Teva Pharmaceutical Industries, Ltd. | Laquinimod for reducing thalamic damage in multiple sclerosis |
| KR20170005434A (ko) * | 2014-04-29 | 2017-01-13 | 테바 파마슈티컬 인더스트리즈 리미티드 | 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드 |
-
2014
- 2014-02-13 WO PCT/US2014/016278 patent/WO2014127139A1/en not_active Ceased
- 2014-02-13 MX MX2015010296A patent/MX2015010296A/es unknown
- 2014-02-13 CA CA2900503A patent/CA2900503A1/en not_active Abandoned
- 2014-02-13 BR BR112015019564A patent/BR112015019564A2/pt active Search and Examination
- 2014-02-13 HK HK16106269.3A patent/HK1218254A1/zh unknown
- 2014-02-13 JP JP2015558130A patent/JP2016510343A/ja active Pending
- 2014-02-13 US US14/180,173 patent/US20140235670A1/en not_active Abandoned
- 2014-02-13 CN CN201480009035.XA patent/CN105163737A/zh active Pending
- 2014-02-13 HK HK16106220.1A patent/HK1218251A1/zh unknown
- 2014-02-13 AU AU2014216199A patent/AU2014216199A1/en not_active Abandoned
- 2014-02-13 PE PE2015001745A patent/PE20151526A1/es not_active Application Discontinuation
- 2014-02-13 KR KR1020157024953A patent/KR20150119227A/ko not_active Withdrawn
- 2014-02-13 EP EP14751103.4A patent/EP2956137A4/en not_active Withdrawn
- 2014-02-13 SG SG11201505818WA patent/SG11201505818WA/en unknown
- 2014-02-13 EA EA201591507A patent/EA201591507A1/ru unknown
- 2014-02-14 TW TW103104987A patent/TW201442709A/zh unknown
- 2014-02-14 UY UY0001035328A patent/UY35328A/es not_active Application Discontinuation
-
2015
- 2015-07-19 IL IL240014A patent/IL240014A0/en unknown
- 2015-08-05 CL CL2015002181A patent/CL2015002181A1/es unknown
-
2017
- 2017-11-13 US US15/811,139 patent/US20180064702A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| PH12014500472A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2014528474A5 (enExample) | ||
| PH12014500239A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2016518387A5 (enExample) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2025137763A (ja) | 絶食条件下でのタシメルテオンの投与 | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| RU2016143979A (ru) | Схема дозирования модулятора s1p с немедленным высвобождением | |
| RU2013127420A (ru) | Способы уменьшения психогенного или компульсивного переедания | |
| JP2015522015A5 (enExample) | ||
| JP2015522077A5 (enExample) | ||
| BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
| JP2018529747A5 (enExample) | ||
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| JP2018500375A5 (enExample) | ||
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| MX2022007304A (es) | Uso de lemborexant para tratamiento del insomnio. | |
| CN112437661A (zh) | 苯甲酸或其盐用于预防或治疗抗n-甲基-d-天冬氨酸受体脑炎的用途 | |
| ZA202205914B (en) | Methods for treating behavioral and psychological symptoms in patients with dementia | |
| ZA202206042B (en) | Treating behavioral and psychological symptoms in dementia patients | |
| HK40041658A (en) | Benzoic acid or a salt thereof for use in preventing or treating anti-n-methyl-d-aspartate receptor encephalitis |